P51 / Research station
Home / Research Library / GHK-Cu Research: Copper Binding & Fibroblast Models
Compound research profile

GHK-Cu Research: Copper Binding & Fibroblast Models

Understand the distinction between GHK and GHK-Cu, a primary fibroblast-culture study, and the limits of translating cellular findings into product claims.

Peptides51 · Published October 9, 2026 · Source-linked educational overview

What is GHK-Cu?

GHK is the tripeptide glycyl-L-histidyl-L-lysine and has affinity for copper(II). GHK-Cu refers to its copper-associated form. The chemical identity matters when comparing research on the peptide with research on the complex.

A primary laboratory study

Maquart and colleagues reported an effect of GHK-Cu on collagen synthesis in fibroblast cultures in 1988. The paper addresses a cellular endpoint under specified experimental conditions; it is not a general demonstration of clinical benefit.

Why the model matters

A culture assay measures activity in a controlled system. It does not reproduce every feature of intact tissue, a formulated product or a human exposure. Formulation and material identity should therefore remain separate questions from the observed assay result.

Reading related literature

Check whether the authors studied GHK, a copper complex, or another copper-containing material. Record the model, endpoint and controls. Do not assume that all articles using the phrase copper peptide studied identical substances.

Sources & further reading

  1. Maquart et al., 1988 — fibroblast-culture study
This overview explains research context and evidence limits. It is not a systematic review or medical guidance. No availability, product quality, or equivalence to study materials is implied. Follow the original source for methods and limitations.

Continue reading

Explore all research guides →

Browse the compound directory →

P51 / Evidence tracker

FDA approval & clinical-trial status

Sources checked 2026-10-10 (UTC). Status describes registry records and named drug products.

FDA / United States

No FDA approval record located

The checked Drugs@FDA ingredient searches did not locate an approval record. This is a database search result, not an exhaustive regulatory determination; compounding eligibility is a separate question.

    FDA database and coverage ↗
    ClinicalTrials.gov

    Active study records reported

    1 active · 0 planned · 0 completed · 1 matching records

    Counts include matching drug or biological interventions in ClinicalTrials.gov. Biomarker-only studies and related compounds are excluded. Registration and a reported phase do not establish safety, efficacy, FDA approval, or that a trial is taking place as described. Check each record and its update date.

    Search the trial registry ↗
    View matching trial records (1)
    Publication archive

    Articles associated with GHK-Cu

    Indexed publications mentioning this compound in their title or abstract, newest first. Follow the original papers for findings and limitations; preprints are labeled.

    Open full source search ↗

    86 indexed matches. Sources checked 2026-10-10 (UTC).

    Search coverage is limited to Europe PMC. Related names, formulations, and study models may differ from listed research materials. A paper mentioning a compound is not necessarily a clinical trial or evidence of effectiveness.